Want to Calculate Fair Value?
Enter Stock | Calculate Fair Value

Stock: UTHR
Book Value Per Share: $151.02
EPS: $27.28
Diluted EPS TTM: $25.12
Dividend Per Share: None
Dividend Yield: 0.00 %
Dividend Payout Ratio: 0%
Price To Sales Ratio TTM: 4.651
Price To Book Ratio: 2.052
PEG Ratio: 1.435
EV To EBITDA: 6.47
P/E Ratio: 12.29
Forward P/E Ratio: 11.35
Ex Dividend Date: None
Dividend Date: None
Current Price: $283.35
Previous Close: $286.14
52 Week Low: $264.33
52 Week High: $417.81
Earning Date (within 30 days): N/A
50 Day MA: $301.31
200 Day MA: $342.8
Link to Yahoo (Financial): UTHR
 
* Note: Prices are in Million (M) USD.
Description:
United Therapeutics Corporation (UTHR) ▼
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
These criteria used Company’s Cash, EBITDA and Debt balance to determines its fair value:
Cash : $1,697 M
Debt : $0 M
EBITDA : $1,555 M

Since Cash is greater than Total Debt, 5 points assigned.
This criteria used industry in which company operates:
Sector: Healthcare
Industry: Biotechnology

Based on industry, 5 points assigned.
This criteria used Company’s Price To Earning (P/E) Ratio to determines its fair value:
Forward PE Ratio: 10.39

Since Forward PE Ratio is less than 15, 5 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Average Free Cash Flow: $326 M
Average Revenue: $1,199 M
Free Cash Flow to Revenue : 27 %

Since Free Cash Flow (FCF) to Revenue percentage is greater than 25, 5 points assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $2,877 M
Revenue 4 Years Ago (2020-12-31): $1,483 M
Last 5 Years Average Revenue Growth: 19%

Since Revenue Growth is between 15 - 20, 4 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $49 M
Share Count 5 Years Ago (2020-12-31): $45 M

Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Earnings Per Share (EPS): $27.28
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0%

Since Dividend Per Share is less than or equal to 0, 0 point assigned.

Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Average ROE: 18%

Since Average ROE is between 10 - 20, 3 points assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $283
52-Week Low: $264
Threshold Price (15% Above 52-Week Low): $304

Since Current price is within 15% threshold, 5 points assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $13,925 M

Since Market Cap is between 10B - 100B, 2 points assigned.
% Exposure to Total Portfolio
Based on the calculated score, we recommend do not exceed 3% exposure of Total Portfolio.
Value-Trade has assigned 34 points to above United Therapeutics Corporation (UTHR) stock.
Twenty Years Avg PE 14, Fair Value PE 25, Industry Based PE is 20 and Growth based PE is 15. Based on these all values average assigned is 18.50.
Value-Trades has assined P/E value 18.50. Since current year earning per share is $27.28.
The fair value of United Therapeutics Corporation (UTHR) stock should be (18.50 x $27.28) = $504.68

Share this valuation:


Advertisement